Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SARS-CoV-2 adjuvanted recombinant protein vaccine (D614 + B.1.351)
- Development stage
- Unknown
- Lead developer
- Sanofi
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
SARS-CoV-2 adjuvanted recombinant protein vaccine (D614 + B.1.351) is a bivalent COVID-19 vaccine candidate developed by Sanofi in collaboration with GSK. It utilizes a recombinant protein subunit platform where the spike (S) proteins of the ancestral SARS-CoV-2 strain (containing the D614 mutation) and the Beta variant (B.1.351) are produced using a baculovirus expression system. The vaccine is formulated with GSK's proprietary AS03 adjuvant, an oil-in-water emulsion containing alpha-tocopherol and squalene, designed to boost the immune response and provide broader protection against multiple variants. In clinical trials, such as the Phase 3 VAT08 study and the jRCT2031210159 trial in Japan, the bivalent formulation was evaluated as both a primary series and a booster to address the evolving landscape of SARS-CoV-2 variants.
- Brand names
- VidPrevtyn
- Other names
- Sanofi-GSK bivalent COVID-19 vaccinebivalent D614 + B.1.351 vaccineSanofi-GSK bivalent recombinant protein vaccine
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on SARS-CoV-2 adjuvanted recombinant protein vaccine (D614 + B.1.351).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SARS-CoV-2 adjuvanted recombinant protein vaccine (D614 + B.1.351).